BSP:B1MR34 (USA)  
Biomarin Pharmaceutical Inc logo

Biomarin Pharmaceutical Inc

R$ 274.67 (0%) Dec 6
P/E:
243.38
P/B:
4.16
Market Cap:
R$ 102.09B ($ 19.54B)
Enterprise V:
R$ 99.40B ($ 19.02B)
Volume:
-
Avg Vol (2M):
818.00
Also Trade In:
Volume:
-
Market Cap R$:
102.09B
Market Cap $:
19.54B
PE Ratio:
243.38
Avg Vol (2-Month):
818.00
Enterprise Value R$:
99.40B
Enterprise Value $:
19.02B
PB Ratio:
4.16
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.
Name Current Vs Industry Vs History
Cash-To-Debt 1.17
Equity-to-Asset 0.73
Debt-to-Equity 0.24
Debt-to-EBITDA 4.97
Interest Coverage 0.37
Piotroski F-Score 8/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.34
Distress
Grey
Safe
Beneish M-Score -2.55
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 96.31
9-Day RSI 91.6
14-Day RSI 84.56
6-1 Month Momentum % 14.71
12-1 Month Momentum % -11.05

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.15
Quick Ratio 3.54
Cash Ratio 2.44
Days Inventory 606.26
Days Sales Outstanding 75.05
Days Payable 151.87

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1

Financials (Next Earnings Date:2023-02-23 Est.)

BSP:B1MR34's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil R$) 10,472.443
EPS (TTM) (R$) 0.937
Beta 0
Volatility % 34.85
14-Day RSI 84.56
14-Day ATR (R$) 4.17934
20-Day SMA (R$) 233.485
12-1 Month Momentum % -11.05
52-Week Range (R$) 179.62 - 275.8
Shares Outstanding (Mil) 371.7

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 8
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biomarin Pharmaceutical Inc Filings

Document Form Filing Date
No Filing Data

Biomarin Pharmaceutical Inc Analysis

Share your research